{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T11:14:00Z","timestamp":1793272440596,"version":"4.5.0"},"reference-count":69,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T00:00:00Z","timestamp":1733702400000},"content-version":"am","delay-in-days":374,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.eprac.2023.07.027","type":"journal-article","created":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T21:05:07Z","timestamp":1692047107000},"page":"999-1006","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":48,"title":["Diagnosis and Management of Pheochromocytomas and Paragangliomas: A Guide for the Clinician"],"prefix":"10.1016","volume":"29","author":[{"given":"Sona","family":"Sharma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8151-5107","authenticated-orcid":false,"given":"Lauren","family":"Fishbein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.eprac.2023.07.027_bib1","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1007\/s12022-022-09704-6","article-title":"Overview of the 2022 WHO classification of paragangliomas and pheochromocytomas","volume":"33","author":"Mete","year":"2022","journal-title":"Endocr Pathol"},{"issue":"1","key":"10.1016\/j.eprac.2023.07.027_bib2","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1530\/EJE-20-0628","article-title":"Epidemiology of pheochromocytoma and paraganglioma: population-based cohort study","volume":"184","author":"Leung","year":"2021","journal-title":"Eur J Endocrinol"},{"issue":"9","key":"10.1016\/j.eprac.2023.07.027_bib3","doi-asserted-by":"crossref","first-page":"bvac105","DOI":"10.1210\/jendso\/bvac105","article-title":"Systematic review: incidence of pheochromocytoma and paraganglioma over 70 years","volume":"6","author":"Al Subhi","year":"2022","journal-title":"J\u00a0Endocr Soc"},{"issue":"11","key":"10.1016\/j.eprac.2023.07.027_bib4","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1002\/cncr.26577","article-title":"Clinical benefits of systemic chemotherapy for patients with metastatic pheochromocytomas or sympathetic extra-adrenal paragangliomas: insights from the largest single-institutional experience","volume":"118","author":"Ayala-Ramirez","year":"2012","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.eprac.2023.07.027_bib5","doi-asserted-by":"crossref","first-page":"3296","DOI":"10.1210\/jc.2017-00992","article-title":"Malignant pheochromocytoma and paraganglioma: 272 patients over 55 years","volume":"102","author":"Hamidi","year":"2017","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.eprac.2023.07.027_bib6","doi-asserted-by":"crossref","first-page":"157","DOI":"10.3803\/EnM.2020.35.1.157","article-title":"Epidemiology and prognosis of pheochromocytoma\/paraganglioma in Korea: a nationwide study based on the National Health Insurance Service","volume":"35","author":"Kim","year":"2020","journal-title":"Endocrinol Metab (Seoul)"},{"issue":"5","key":"10.1016\/j.eprac.2023.07.027_bib7","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1210\/jc.2018-01707","article-title":"Pheochromocytoma characteristics and behavior differ depending on method of discovery","volume":"104","author":"Gruber","year":"2019","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.eprac.2023.07.027_bib8","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1245\/s10434-020-08220-3","article-title":"Update on pheochromocytoma and paraganglioma from the SSO Endocrine\/Head and Neck Disease-Site Work Group. Part 1 of 2: Advances in Pathogenesis and Diagnosis of Pheochromocytoma and Paraganglioma","volume":"27","author":"Patel","year":"2020","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"10.1016\/j.eprac.2023.07.027_bib9","first-page":"271","article-title":"Pheochromocytoma and paraganglioma: from clinical findings to diagnosis","volume":"54","author":"Aygun","year":"2020","journal-title":"Sisli Etfal Hastan Tip Bul"},{"issue":"12","key":"10.1016\/j.eprac.2023.07.027_bib10","doi-asserted-by":"crossref","first-page":"bvab163","DOI":"10.1210\/jendso\/bvab163","article-title":"Dopamine-secreting pheochromocytoma and paraganglioma","volume":"5","author":"Miyamoto","year":"2021","journal-title":"J\u00a0Endocr Soc"},{"issue":"6","key":"10.1016\/j.eprac.2023.07.027_bib11","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1016\/j.dsx.2020.10.030","article-title":"Diabetes mellitus in pheochromocytoma and paraganglioma: prevalence, dynamics of insulin secretion\/sensitivity and predictors of remission","volume":"14","author":"Khatiwada","year":"2020","journal-title":"Diabetes Metab Syndr"},{"issue":"2","key":"10.1016\/j.eprac.2023.07.027_bib12","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s42000-021-00274-6","article-title":"Pheochromocytoma\/paraganglioma crisis: case series from a tertiary referral center for pheochromocytomas and paragangliomas","volume":"20","author":"Meijs","year":"2021","journal-title":"Hormones (Athens)"},{"issue":"4","key":"10.1016\/j.eprac.2023.07.027_bib13","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.31083\/j.rcm2204130","article-title":"Catecholamine-induced cardiomyopathy: an endocrinologist's perspective","volume":"22","author":"Kumar","year":"2021","journal-title":"Rev Cardiovasc Med"},{"issue":"7","key":"10.1016\/j.eprac.2023.07.027_bib14","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/s41574-021-00492-3","article-title":"International consensus on initial screening and follow-up of asymptomatic SDHx mutation carriers","volume":"17","author":"Amar","year":"2021","journal-title":"Nat Rev Endocrinol"},{"issue":"4","key":"10.1016\/j.eprac.2023.07.027_bib15","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1097\/MPA.0000000000001792","article-title":"The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Management of Metastatic and\/or Unresectable Pheochromocytoma and Paraganglioma","volume":"50","author":"Fishbein","year":"2021","journal-title":"Pancreas"},{"issue":"6","key":"10.1016\/j.eprac.2023.07.027_bib16","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1210\/jc.2014-1498","article-title":"Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline","volume":"99","author":"Lenders","year":"2014","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"11","key":"10.1016\/j.eprac.2023.07.027_bib17","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1016\/j.ejca.2011.07.016","article-title":"Plasma methoxytyramine: a novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status","volume":"48","author":"Eisenhofer","year":"2012","journal-title":"Eur J Cancer"},{"issue":"11","key":"10.1016\/j.eprac.2023.07.027_bib18","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1373\/clinchem.2018.291369","article-title":"Biochemical diagnosis of chromaffin cell tumors in patients at high and low risk of disease: plasma versus urinary free or deconjugated O-methylated catecholamine metabolites","volume":"64","author":"Eisenhofer","year":"2018","journal-title":"Clin Chem"},{"key":"10.1016\/j.eprac.2023.07.027_bib19","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.clinbiochem.2020.01.005","article-title":"Very high rate of false positive biochemical results when screening for pheochromocytoma in a large, undifferentiated population with variable indications for testing","volume":"77","author":"Kline","year":"2020","journal-title":"Clin Biochem"},{"issue":"6","key":"10.1016\/j.eprac.2023.07.027_bib20","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1053\/j.ajkd.2018.06.018","article-title":"Optimized reference intervals for plasma free metanephrines in patients with CKD","volume":"72","author":"Pamporaki","year":"2018","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"10.1016\/j.eprac.2023.07.027_bib21","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s11886-021-01624-x","article-title":"Pseudopheochromocytoma: an uncommon cause of severe hypertension","volume":"24","author":"Turin","year":"2022","journal-title":"Curr Cardiol Rep"},{"issue":"10","key":"10.1016\/j.eprac.2023.07.027_bib22","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1016\/j.mayocp.2019.03.030","article-title":"Diagnostic accuracy of computed tomography to exclude pheochromocytoma: a systematic review, meta-analysis, and cost analysis","volume":"94","author":"Buitenwerf","year":"2019","journal-title":"Mayo Clinic proceedings Mayo Clinic"},{"issue":"2","key":"10.1016\/j.eprac.2023.07.027_bib23","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1210\/jc.2018-01532","article-title":"CT characteristics of pheochromocytoma: relevance for the evaluation of adrenal incidentaloma","volume":"104","author":"Canu","year":"2019","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"8","key":"10.1016\/j.eprac.2023.07.027_bib24","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1177\/0284185119889568","article-title":"Diagnostic performance of adrenal CT in the differentiation of adenoma and pheochromocytoma","volume":"61","author":"Altinmakas","year":"2020","journal-title":"Acta Radiol"},{"issue":"1","key":"10.1016\/j.eprac.2023.07.027_bib25","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.1038\/s41598-022-06655-0","article-title":"Predictive model of pheochromocytoma based on the imaging features of the adrenal tumours","volume":"12","author":"Araujo-Castro","year":"2022","journal-title":"Sci Rep"},{"issue":"3","key":"10.1016\/j.eprac.2023.07.027_bib26","doi-asserted-by":"crossref","first-page":"369","DOI":"10.2967\/jnumed.118.211706","article-title":"Performance of (68)Ga-DOTA-conjugated somatostatin receptor-targeting peptide PET in detection of pheochromocytoma and paraganglioma: a systematic review and metaanalysis","volume":"60","author":"Han","year":"2019","journal-title":"J\u00a0Nucl Med"},{"issue":"5","key":"10.1016\/j.eprac.2023.07.027_bib27","doi-asserted-by":"crossref","first-page":"623","DOI":"10.2967\/jnumed.118.217463","article-title":"Efficacy and safety of high-specific-activity (131)I-MIBG therapy in patients with advanced pheochromocytoma or paraganglioma","volume":"60","author":"Pryma","year":"2019","journal-title":"J\u00a0Nucl Med"},{"issue":"5","key":"10.1016\/j.eprac.2023.07.027_bib28","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1245\/s10434-013-2942-5","article-title":"Inherited mutations in pheochromocytoma and paraganglioma: why all patients should be offered genetic testing","volume":"20","author":"Fishbein","year":"2013","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"10.1016\/j.eprac.2023.07.027_bib29","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1210\/jc.2016-3829","article-title":"Characteristics of pediatric vs adult pheochromocytomas and paragangliomas","volume":"102","author":"Pamporaki","year":"2017","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.eprac.2023.07.027_bib30","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nrendo.2014.188","article-title":"Paraganglioma and phaeochromocytoma: from genetics to personalized medicine","volume":"11","author":"Favier","year":"2015","journal-title":"Nat Rev Endocrinol"},{"issue":"5","key":"10.1016\/j.eprac.2023.07.027_bib31","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1530\/ERC-19-0024","article-title":"Genotype-phenotype correlations in pheochromocytoma and paraganglioma: a systematic review and individual patient meta-analysis","volume":"26","author":"Crona","year":"2019","journal-title":"Endocr Relat Cancer"},{"issue":"1","key":"10.1016\/j.eprac.2023.07.027_bib32","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/gim.2014.147","article-title":"A\u00a0practice guideline from the American College of Medical Genetics and Genomics and the National Society of Genetic Counselors: referral indications for cancer predisposition assessment","volume":"17","author":"Hampel","year":"2015","journal-title":"Genet Med"},{"issue":"8","key":"10.1016\/j.eprac.2023.07.027_bib33","article-title":"von Hippel-Lindau disease: updated guideline for diagnosis and surveillance","volume":"65","author":"Louise","year":"2022","journal-title":"Eur J Med Genet"},{"issue":"2","key":"10.1016\/j.eprac.2023.07.027_bib34","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1136\/jmg.2006.045906","article-title":"Guidelines for the diagnosis and management of individuals with neurofibromatosis 1","volume":"44","author":"Ferner","year":"2007","journal-title":"J\u00a0Med Genet"},{"issue":"6","key":"10.1016\/j.eprac.2023.07.027_bib35","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1089\/thy.2014.0335","article-title":"Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma","volume":"25","author":"Wells","year":"2015","journal-title":"Thyroid"},{"issue":"5","key":"10.1016\/j.eprac.2023.07.027_bib36","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S2213-8587(23)00038-4","article-title":"Clinical consensus guideline on the management of phaeochromocytoma and paraganglioma in patients harbouring germline SDHD pathogenic variants","volume":"11","author":"Taieb","year":"2023","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"10.1016\/j.eprac.2023.07.027_bib37","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1136\/jmedgenet-2021-108355","article-title":"UK recommendations for SDHA germline genetic testing and surveillance in clinical practice","volume":"60","author":"Hanson","year":"2023","journal-title":"J\u00a0Med Genet"},{"issue":"12","key":"10.1016\/j.eprac.2023.07.027_bib38","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1038\/s41436-020-0921-3","article-title":"Tumor detection rates in screening of individuals with SDHx-related hereditary paraganglioma-pheochromocytoma syndrome","volume":"22","author":"Greenberg","year":"2020","journal-title":"Genet Med"},{"issue":"5","key":"10.1016\/j.eprac.2023.07.027_bib39","doi-asserted-by":"crossref","first-page":"e1907","DOI":"10.1210\/clinem\/dgac019","article-title":"Surveillance improves outcomes for carriers of SDHB pathogenic variants: a multicenter study","volume":"107","author":"Davidoff","year":"2022","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"11","key":"10.1016\/j.eprac.2023.07.027_bib40","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1177\/0003489420931540","article-title":"The changing paradigm of head and neck paragangliomas: what every otolaryngologist needs to know","volume":"129","author":"Cass","year":"2020","journal-title":"Ann Otol Rhinol Laryngol"},{"issue":"1","key":"10.1016\/j.eprac.2023.07.027_bib41","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s00423-021-02312-8","article-title":"Minimally invasive adrenalectomy for large pheochromocytoma: not recommendable yet? Results from a single institution case series","volume":"407","author":"Arolfo","year":"2022","journal-title":"Langenbecks Arch Surg"},{"issue":"1","key":"10.1016\/j.eprac.2023.07.027_bib42","doi-asserted-by":"crossref","first-page":"R9","DOI":"10.1530\/EJE-15-0549","article-title":"Management of endocrine disease: outcome of adrenal sparing surgery in heritable pheochromocytoma","volume":"174","author":"Castinetti","year":"2016","journal-title":"Eur J Endocrinol"},{"issue":"8","key":"10.1016\/j.eprac.2023.07.027_bib43","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.8898","article-title":"Comparison of pheochromocytoma-specific morbidity and mortality among adults with bilateral pheochromocytomas undergoing total adrenalectomy vs cortical-sparing adrenalectomy","volume":"2","author":"Neumann","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"2","key":"10.1016\/j.eprac.2023.07.027_bib44","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1093\/bja\/aew392","article-title":"Perioperative alpha-receptor blockade in phaeochromocytoma surgery: an observational case series","volume":"118","author":"Groeben","year":"2017","journal-title":"Br J Anaesth"},{"issue":"2","key":"10.1016\/j.eprac.2023.07.027_bib45","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1007\/s00464-020-07439-1","article-title":"Pheochromocytoma surgery without systematic preoperative pharmacological preparation: insights from a referral tertiary center experience","volume":"35","author":"Buisset","year":"2021","journal-title":"Surg Endosc"},{"issue":"1","key":"10.1016\/j.eprac.2023.07.027_bib46","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/cen.13066","article-title":"Are patients with hormonally functional phaeochromocytoma and paraganglioma initially receiving a proper adrenoceptor blockade? A retrospective cohort study","volume":"85","author":"Luiz","year":"2016","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"2","key":"10.1016\/j.eprac.2023.07.027_bib47","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1210\/jc.2014-2998","article-title":"Per-operative hemodynamic instability in normotensive patients with incidentally discovered pheochromocytomas","volume":"100","author":"Lafont","year":"2015","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.eprac.2023.07.027_bib48","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1530\/EJE-20-1301","article-title":"Selective vs non-selective alpha-blockade prior to adrenalectomy for pheochromocytoma: systematic review and meta-analysis","volume":"184","author":"Zawadzka","year":"2021","journal-title":"Eur J Endocrinol"},{"issue":"7","key":"10.1016\/j.eprac.2023.07.027_bib49","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1210\/clinem\/dgz188","article-title":"Efficacy of alpha-blockers on hemodynamic control during pheochromocytoma resection: a randomized controlled trial","volume":"105","author":"Buitenwerf","year":"2020","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.eprac.2023.07.027_bib50","doi-asserted-by":"crossref","DOI":"10.1530\/EC-21-0539","article-title":"Preoperative blood pressure targets and effect on hemodynamics in pheochromocytoma and paraganglioma","volume":"11","author":"Ugleholdt","year":"2022","journal-title":"Endocr Connect"},{"issue":"Suppl 3","key":"10.1016\/j.eprac.2023.07.027_bib51","doi-asserted-by":"crossref","first-page":"S646","DOI":"10.1245\/s10434-015-4862-z","article-title":"Preoperative metyrosine improves cardiovascular outcomes for patients undergoing surgery for pheochromocytoma and paraganglioma","volume":"22","author":"Wachtel","year":"2015","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"10.1016\/j.eprac.2023.07.027_bib52","doi-asserted-by":"crossref","first-page":"e2393","DOI":"10.1210\/clinem\/dgab130","article-title":"The role for metyrosine in the treatment of patients with pheochromocytoma and paraganglioma","volume":"106","author":"Gruber","year":"2021","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.eprac.2023.07.027_bib53","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1097\/00045415-200201000-00009","article-title":"Pheochromocytoma","volume":"10","author":"Bravo","year":"2002","journal-title":"Cardiol Rev"},{"issue":"3","key":"10.1016\/j.eprac.2023.07.027_bib54","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1007\/s00268-020-05866-8","article-title":"Bi-national review of phaeochromocytoma care: is ICU admission always necessary?","volume":"45","author":"Papachristos","year":"2021","journal-title":"World J Surg"},{"issue":"1","key":"10.1016\/j.eprac.2023.07.027_bib55","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.surg.2015.06.045","article-title":"Selective strategy for intensive monitoring after pheochromocytoma resection","volume":"159","author":"Benay","year":"2016","journal-title":"Surgery"},{"issue":"5","key":"10.1016\/j.eprac.2023.07.027_bib56","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1097\/00000478-200205000-00002","article-title":"Pheochromocytoma of the Adrenal gland Scaled Score (PASS) to separate benign from malignant neoplasms: a clinicopathologic and immunophenotypic study of 100 cases","volume":"26","author":"Thompson","year":"2002","journal-title":"Am J Surg Pathol"},{"issue":"4","key":"10.1016\/j.eprac.2023.07.027_bib57","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1097\/PAS.0b013e318190d12e","article-title":"Observer variation in the application of the Pheochromocytoma of the Adrenal Gland Scaled Score","volume":"33","author":"Wu","year":"2009","journal-title":"Am J Surg Pathol"},{"issue":"12","key":"10.1016\/j.eprac.2023.07.027_bib58","doi-asserted-by":"crossref","first-page":"e4661","DOI":"10.1210\/clinem\/dgaa608","article-title":"Predicting metastatic potential in pheochromocytoma and paraganglioma: a comparison of PASS and GAPP scoring systems","volume":"105","author":"Wachtel","year":"2020","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.eprac.2023.07.027_bib59","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1530\/ERC-13-0494","article-title":"Pathological grading for predicting metastasis in phaeochromocytoma and paraganglioma","volume":"21","author":"Kimura","year":"2014","journal-title":"Endocr Relat Cancer"},{"issue":"11","key":"10.1016\/j.eprac.2023.07.027_bib60","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0187398","article-title":"Validation of pathological grading systems for predicting metastatic potential in pheochromocytoma and paraganglioma","volume":"12","author":"Koh","year":"2017","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.eprac.2023.07.027_bib61","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s00428-019-02553-5","article-title":"COPPS, a composite score integrating pathological features, PS100 and SDHB losses, predicts the risk of metastasis and progression-free survival in pheochromocytomas\/paragangliomas","volume":"474","author":"Pierre","year":"2019","journal-title":"Virchows Arch"},{"issue":"1","key":"10.1016\/j.eprac.2023.07.027_bib62","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s12020-021-02854-3","article-title":"Assessment of the AJCC staging system of pheochromocytomas\/paragangliomas","volume":"75","author":"Abdel-Rahman","year":"2022","journal-title":"Endocrine"},{"issue":"10","key":"10.1016\/j.eprac.2023.07.027_bib63","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.3390\/cancers11101505","article-title":"Current management of pheochromocytoma\/paraganglioma: a guide for the practicing clinician in the era of precision medicine","volume":"11","author":"Nolting","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.eprac.2023.07.027_bib64","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1530\/ERC-13-0415","article-title":"Long-term prognosis of patients with pediatric pheochromocytoma","volume":"21","author":"Bausch","year":"2014","journal-title":"Endocr Relat Cancer"},{"issue":"8","key":"10.1016\/j.eprac.2023.07.027_bib65","doi-asserted-by":"crossref","first-page":"L51","DOI":"10.1530\/ERC-17-0086","article-title":"SDHB mutation carriers with malignant pheochromocytoma respond better to CVD","volume":"24","author":"Fishbein","year":"2017","journal-title":"Endocr Relat Cancer"},{"issue":"1","key":"10.1016\/j.eprac.2023.07.027_bib66","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S2213-8587(20)30363-6","article-title":"Maternal and fetal outcomes in phaeochromocytoma and pregnancy: a multicentre retrospective cohort study and systematic review of literature","volume":"9","author":"Bancos","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9","key":"10.1016\/j.eprac.2023.07.027_bib67","doi-asserted-by":"crossref","first-page":"dgaa441","DOI":"10.1210\/clinem\/dgaa441","article-title":"Approach to the patient: perioperative management of the patient with pheochromocytoma or sympathetic paraganglioma","volume":"105","author":"Berends","year":"2020","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.eprac.2023.07.027_bib68","doi-asserted-by":"crossref","unstructured":"UpToDate Waltham, MA: UpToDate; Accessed on June 6, 2023.","DOI":"10.1097\/01.COT.0000918288.02548.c7"},{"key":"10.1016\/j.eprac.2023.07.027_bib69","series-title":"AJCC cancer staging manual","author":"Amin","year":"2017"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X23005037?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X23005037?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T22:15:08Z","timestamp":1761516908000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X23005037"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":69,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["S1530891X23005037"],"URL":"https:\/\/doi.org\/10.1016\/j.eprac.2023.07.027","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Diagnosis and Management of Pheochromocytomas and Paragangliomas: A Guide for the Clinician","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eprac.2023.07.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 AACE. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}